VNDA Vanda Pharmaceuticals Inc.

10.98
+0.71  (+7%)
Previous Close 10.27
Open 10.65
Price To Book 1.43
Market Cap 589,061,815
Shares 53,648,617
Volume 670,272
Short Ratio
Av. Daily Volume 812,650
Stock charts supplied by TradingView

NewsSee all news

  1. Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

    WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (NASDAQ:VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The

  2. Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences

    WASHINGTON, Feb. 27, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020: The Cowen and Company

  3. Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis

    WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic

  4. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2019. "We had

  5. Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors

    WASHINGTON, Feb. 19, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announces the appointment of Stephen Ray Mitchell, M.D. to its Board of Directors. "Ray is a highly respected leader in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
CRL issued August 19, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Refusal-to-file letter issued by the FDA for sNDA filing - March 13, 2020.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 trial did not meet primary endpoint - February 25, 2020.
Tradipitant - EPIONE 1
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 3 data due 2020.
Tradipitant
Motion sickness
Phase 3 trial to commence 4Q 2019.
Fanapt
Bipolar Disorder
Phase 3 trial to be initiated by YE 2019.
HETLIOZ (tasimelteon)
Delayed sleep phase disorder (DSPD)
Phase 3 enrolment commenced October 2019.
Tradipitant - EPIONE 2
Atopic dermatitis
Phase 3 enrolment to commence April 2020.
Tradipitant
Pneumonia associated with COVID-19

Latest News

  1. Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

    WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (NASDAQ:VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The

  2. Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences

    WASHINGTON, Feb. 27, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020: The Cowen and Company

  3. Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis

    WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic

  4. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2019. "We had

  5. Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors

    WASHINGTON, Feb. 19, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announces the appointment of Stephen Ray Mitchell, M.D. to its Board of Directors. "Ray is a highly respected leader in

  6. Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

    WASHINGTON, Feb. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market

  7. Vanda Pharmaceuticals Comments on Court Ruling

    WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in

  8. Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®

    WASHINGTON, Jan. 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals

  9. Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award

    WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will

  10. Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences

    WASHINGTON, Nov. 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019: The Stifel 2019

  11. Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

    WASHINGTON, Nov. 6, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019. "These results affirm

  12. Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

    WASHINGTON, Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday,

  13. Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors

    WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019. Following

  14. Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies

    WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high